The clinical efficacy of CDK4/6 inhibitors has transformed the landscape of metastatic breast cancer treatment, with improved outcomes even in the presence of certain mutations that contribute to endocrine resistance [5,13]. The gene discussed is CDK4; the disease is breast carcinoma.